Hinova Pharmaceuticals Inc
688302
Company Profile
Business description
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
Contact
No. 5 Keyuan South Road
No. 2 and 3, 4th Floor, Building 1, Rongyao Building
High-tech Zone, Sichuan Province
Chengdu610041
CHNT: +86 2885058465
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
241
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,275.34 | 31.05 | 0.38% |
| DAX 40 | 24,969.70 | 24.75 | 0.10% |
| Dow JONES (US) | 51,561.93 | 874.86 | 1.73% |
| FTSE 100 | 10,398.05 | 37.73 | 0.36% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 26,830.96 | 23.02 | -0.09% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,584.31 | 30.63 | 0.41% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |